Clinical Trials
4 trialsNCT01199068 2021-05-13
CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
Daiichi Sankyo
Phase 1 Completed
NCT00408434 2020-10-19
Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer
Daiichi Sankyo
Phase 1 Completed
NCT00603941 2020-09-16
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
Daiichi Sankyo
Phase 1/2 Terminated
NCT01199055 2020-07-07
CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
Daiichi Sankyo
Phase 1 Completed